Artivion acquires Endospan after FDA approval

Artivion>>>, a medical device company, completed the acquisition of Endospan>>>, a pioneer in endovascular solutions for complex aortic pathologies. The acquisition, valued at $135 million upfront with potential for an additional $200 million based on commercial performance, follows the United States — Food and Drug Administration>>>'s PMA approval in April 2026 for Endospan>>>'s Nexus Aortic Arch System>>>. This system is the first off-the-shelf endovascular solution for aortic arch disease. Artivion>>> funded the upfront payment using a $150 million delayed draw term loan. The deal solidifies Artivion>>>'s market-leading position by completing its three-pronged aortic arch portfolio, which includes AMDS and ARCEVO LSA technologies, and adds a robust pipeline of next-generation arch technologies. Artivion>>> had previously been the exclusive distributor of the Nexus Aortic Arch System>>> in Europe, the Middle East and Africa>>> since 2019.